SCHEMBL5864546

SCHEMBL5864546

COc1cc2ncnc(Nc3ccc(O)c(Cl)c3)c2cc1OC

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.82
RET P07949 10/20 0.82
KIF5B P33176 9/20 0.82
EGFR P00533 10/20 0.74
JAK3 P52333 2/20 0.74
CLK1 P49759 2/20 0.74
ABCG2 Q9UNQ0 2/20 0.74
FBP1 P09467 2/20 0.74
AURKA O14965 1/20 0.74
ERBB2 P04626 1/20 0.74
INSR P06213 1/20 0.74
PDGFRB P09619 1/20 0.74
FLT4 P35916 1/20 0.74
EPHB4 P54760 1/20 0.74
TEK Q02763 1/20 0.74
AURKB Q96GD4 1/20 0.74
ABCB1 P08183 1/20 0.74
RIPK2 O43353 2/20 0.71
FLT1 P17948 2/20 0.71
GAK O14976 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7870579 0.90 KDR (1.00) KDRRETKIF5BEGFRJAK3
Hydrochloric Acid SCHEMBL7867185 0.89 KDR (0.98) KDRRETKIF5BEGFRJAK3
SCHEMBL22590721 0.89 EGFR (0.80) KDRRETKIF5BEGFRJAK3
SCHEMBL2100447 0.89 KDR (0.80) KDRRETKIF5BEGFRCLK1
SCHEMBL907182 0.87 KDR (0.77) KDRRETKIF5BEGFRJAK3
SCHEMBL22630825 0.87 KDR (0.77) KDRRETKIF5BEGFRJAK3
SCHEMBL6068633 0.86 KDR (0.82) KDRRETKIF5BEGFRJAK3
SCHEMBL6668470 0.86 JAK3 (0.73) KDRRETKIF5BEGFRJAK3
SCHEMBL14095961 0.85 EGFR (0.80) KDRRETKIF5BEGFRJAK3
SCHEMBL30505605 0.85 EGFR (1.00) KDREGFRCLK1FBP1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE 2004-02-26 US claimed
JP-2002540103-A 2002-11-26 JP claimed
US-20020137757-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2002-09-26 US claimed
US-20020111360-A1 Quinazoline formulations and therapeutic use thereof PARKER HUGHES INSTITUTE 2002-08-15 US claimed
EP-1163228-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP claimed
EP-1162974-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP claimed
US-20010016588-A1 Quinazolines and therapeutic use thereof HUGHES INSTITUTE (US) 2001-08-23 US claimed
US-6258820-B1 ANTITUMOR AGENTS PARKER HUGHES INSTITUTE 2001-07-10 US claimed
WO-2000056720-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO claimed
WO-2000056338-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO claimed
WO-2017040459-A1 IMPROVED SOLUBILITY FOR TARGET COMPOUNDS Aunova Medchem LLC (US) 2017-03-09 WO disclosed
US-7038049-B2 Haloanilino quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2006-05-02 US disclosed
US-20050075353-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2005-04-07 US disclosed
WO-2004013091-A2 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-02-12 WO disclosed
US-6638939-B2 Anticancer agents PARKER HUGHES INSTITUTE 2003-10-28 US disclosed
WO-2001035952-A2 RADIOSENSITIZATION OF HUMAN GLIOBLASTOMA CELLS BY QUINAZOLINE COMPOUNDS PARKER HUGUES INSTITUTE (US) 2001-05-25 WO disclosed
EP-1100787-A1 LIPID-LOWERING QUINAZOLINE DERIVATIVE Parker Hughes Institute (US) 2001-05-23 EP disclosed
WO-2000056720-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO disclosed
WO-2000056338-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO disclosed
WO-2000006554-A1 LIPID-LOWERING QUINAZOLINE DERIVATIVE PARKER HUGHES INSTITUTE (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075353-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885RET 1370/4885KIF5B 3899/4885
US-20020111360-A1 Quinazoline formulations and therapeutic use thereof CMA1, MAST3, MAST1 KDR 2810/4885RET 2800/4885KIF5B 3284/4885
US-20020137757-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885RET 1370/4885KIF5B 3899/4885
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof HRH2, HNMT, HRH4 KDR 2273/4885RET 1115/4885KIF5B 3041/4885
US-20010016588-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885RET 1370/4885KIF5B 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.